Discovery of a Novel Inhaled PI3Kδ Inhibitor for the Treatment of Respiratory Diseases

Oral PI3Kδ inhibitors such as Idelalisib and Duvelisib have shown efficacy as anticancer agents and Idelalisib has been approved for the treatment of three B-cell cancers. However, Idelalisib has a black box warning on its product label regarding the risks of fatal and serious toxicities including h...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of medicinal chemistry 2018-11, Vol.61 (21), p.9551-9567
Hauptverfasser:	Erra, Montse, Taltavull, Joan, Bernal, Francisco Javier, Caturla, Juan Francisco, Carrascal, Marta, Pagès, Lluís, Mir, Marta, Espinosa, Sònia, Gràcia, Jordi, Domínguez, María, Sabaté, Mar, Paris, Stéphane, Maldonado, Mónica, Hernández, Begoña, Bravo, Mónica, Calama, Elena, Miralpeix, Montserrat, Lehner, Martin D, Calbet, Marta
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!